Current situation of oncology biosimilars in Japan.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. Regulatory and safety challenges of biosimilars: insights from developed and emerging economies.European journal of clinical pharmacology · 2026
   Review
2. Demand- Versus Supply-Side Policies in Market Penetration of Biosimilars: Which is More Effective?BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025
   Article
3. A descriptive analysis of real-world oncology biosimilar use in Japan.Future oncology (London, England) · 2024
   Observational

Corrections and comments

• Comment on
  Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions.2020

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as